ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Pharma Equity Group A/s

Pharma Equity Group A/s (0REU)

0.40
0.00
(0.00%)
Closed January 05 11:30AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.40
Bid
0.00
Ask
0.00
Volume
0.00
0.00 Day's Range 0.00
0.40 52 Week Range 0.40
Market Cap
Previous Close
0.40
Open
-
Last Trade
(O)
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
0.00
Shares Outstanding
1,022,964,000
Dividend Yield
-
PE Ratio
-16.60
Earnings Per Share (EPS)
-0.02
Revenue
-
Net Profit
-24.61M

About Pharma Equity Group A/s

Sector
Investors, Nec
Industry
Money Management
Headquarters
Copenhagen, Dnk
Founded
2002
Pharma Equity Group A/s is listed in the Investors sector of the London Stock Exchange with ticker 0REU. The last closing price for Pharma Equity Group A/s was kr0.40. Over the last year, Pharma Equity Group A/s shares have traded in a share price range of kr 0.40 to kr 0.40.

Pharma Equity Group A/s currently has 1,022,964,000 shares outstanding. The market capitalization of Pharma Equity Group A/s is kr409.19 million. Pharma Equity Group A/s has a price to earnings ratio (PE ratio) of -16.60.

0REU Latest News

The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.

The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.       The Board of Directors' decision on a new execution...

Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/S

Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/S...

Consolidated Interim report 1 January – 30 September 2024

Consolidated Interim report 1 January – 30 September 2024 Consolidated Interim report 1 January – 30 September 2024 Company announcement no. 30 – November 15, 2024 Key points from the Q1-Q3-2024...

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.      Pharma Equity Group's...

Major shareholder announcement - Pharma Equity Group A/S

Major shareholder announcement - Pharma Equity Group A/S      Major shareholder announcement - Pharma Equity Group A/S 14 October 2024Announcement No. 28  Pharma Equity Group A/S has, in...

Managers’ transactions 

Managers’ transactions  October 14,2024Announcement no. 27 Managers’ transactions  Pharma Equity Group A/S has today received notification pursuant to article 19 of Regulation (EU) no. 596/2014...

Pharma Equity Group announces successful completion of directed issue of new shares

Pharma Equity Group announces successful completion of directed issue of new shares      Pharma Equity Group announces successful completion of directed issue of new shares 11 October 2024Company...

Pharma Equity Group announces issuance of new shares in a direct issue

Pharma Equity Group announces issuance of new shares in a direct issue      Pharma Equity Group announces issuance of new shares in a direct issue  Inside information4 October 2024Company...

Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights

Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights      Registration of capital reduction by way of a...

Consolidated Interim Report 1 January – 30 June 2024

Consolidated Interim Report 1 January – 30 June 2024 Consolidated Interim Report 1 January – 30 June 2024 Company announcement no. 23 – August 16, 2024 Key points from the H1-2024 report (period 1...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1000.40.40.400DE
4000.40.40.400DE
12000.40.40.400DE
26000.40.40.400DE
52000.40.40.400DE
156000.40.40.400DE
260000.40.40.400DE

0REU - Frequently Asked Questions (FAQ)

What is the current Pharma Equity Group A/s share price?
The current share price of Pharma Equity Group A/s is kr 0.40
How many Pharma Equity Group A/s shares are in issue?
Pharma Equity Group A/s has 1,022,964,000 shares in issue
What is the market cap of Pharma Equity Group A/s?
The market capitalisation of Pharma Equity Group A/s is DKK 409.19M
What is the 1 year trading range for Pharma Equity Group A/s share price?
Pharma Equity Group A/s has traded in the range of kr 0.40 to kr 0.40 during the past year
What is the PE ratio of Pharma Equity Group A/s?
The price to earnings ratio of Pharma Equity Group A/s is -16.6
What is the reporting currency for Pharma Equity Group A/s?
Pharma Equity Group A/s reports financial results in DKK
What is the latest annual profit for Pharma Equity Group A/s?
The latest annual profit of Pharma Equity Group A/s is DKK -24.61M
What is the registered address of Pharma Equity Group A/s?
The registered address for Pharma Equity Group A/s is VESTER FARIMAGSGADE 1, 2, COPENHAGEN, DK-2900
What is the Pharma Equity Group A/s website address?
The website address for Pharma Equity Group A/s is www.blue-vision.dk
Which industry sector does Pharma Equity Group A/s operate in?
Pharma Equity Group A/s operates in the MONEY MANAGEMENT sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TCFTheracryf Plc
0.725p
(38.10%)
7.56M
NMTNeometals Ltd
3.50p
(27.27%)
346.81k
SCHOScholium Group Plc
44.00p
(25.71%)
30.65k
FABFusion Antibodies Plc
10.15p
(24.54%)
3.34M
PYXPyx Resources Limited
3.49p
(22.24%)
8.43k
TM1Technology Minerals Plc
0.125p
(-24.24%)
37.21M
QUIZQuiz Plc
0.70p
(-18.60%)
3.67M
SYMESupply@me Capital Plc
0.003p
(-17.81%)
168.35M
OBDOxford Biodynamics Plc
1.20p
(-14.29%)
827.83k
ZENZenith Energy Ltd.
5.25p
(-13.93%)
5.39M
TRPTower Resources Plc
0.0395p
(5.33%)
539.51M
CPXCap-xx Limited
0.1825p
(1.39%)
494M
NTVONativo Resources Plc
0.0019p
(0.00%)
320.16M
DGIDg Innovate Plc
0.0225p
(-13.46%)
208.21M
ENETEthernity Networks Ltd
0.1125p
(2.27%)
207.56M

Discussion

View Full Feed
MightyX MightyX 6 minutes ago
Yet no one is innocent
TPTW
BIG D 4 BIG D 4 7 minutes ago
WOW !! HAPPY NEW YEAR TO ALL THE LONGS HERE !! I HAVE 2 NAYSAYERS ON IGNORE SO I NEVER READ THEIR BS !! GO SAVING GRACE-- JJ AND ALL THE NEW POSTERS WHO ARE POSITIVE !! .02 CENTS TO START THE RUN TO ONE DOLLAR IS WHERE WE SHOULD BE !! THIS STOCK IS SUCH A GREAT BUY HERE !! I AM LOADED WITH 32 MILLI
MJNA
MightyX MightyX 7 minutes ago
The judicial system legitimizes prosecution
TPTW
jondoeuk jondoeuk 8 minutes ago
A new paper. From it: 'BNT221 was well tolerated across both DLs, with no dose-limiting toxicities of grade 3 or higher attributed to the T cell product observed. Specifically, no cytokine release, immune effector cell-associated neurotoxicity or macrophage activation syndromes were reported. A dose
BNTX
benz280c benz280c 9 minutes ago
Nice to see you are bullish. This quote may round out your knowledge.
"It is worthy to note that a new CUSIP has been approved by the CUSIP Global Services (CGS).
Subsequently, we have submitted a corporation action with FINRA for a Company name change, Ticker Symbol Change and Cusip
GDVM
shajandr shajandr 10 minutes ago
Sorry to read that you're still feeling sick. I posted a week or two ago about 41 bunnies and also some cats and dogs that were rescued from a home in Delaware county, Iowa and that were transferred to the DBQ county animal shelter. I just spoke with DaSqu_w and she went to the animal shelter to see
Lakota-45 Lakota-45 11 minutes ago
Will do, but I doubt they will listen !!!

~ Lol !!!
IONI
boi568 boi568 12 minutes ago
Probably
AVXL
HokieHead HokieHead 14 minutes ago
Wrong..
TWOH
HokieHead HokieHead 15 minutes ago
Get your facts straight, the halt was in the Canadian side as they are reviewing all the disclosures submitted, there’s ZERO issues in the US, it’s a fully reporting SEC company.
TWOH
Lakota-45 Lakota-45 16 minutes ago
I agree with you 'farmI1234 !!!

I'm pretty sure most of the Savvy Investors, that have been paying attention,
have been loading the dips, and .0004's, for a while now.
I know I have, along with fishing down stream.

I doubt any Longs will get caught short,
WDLF
CaptHowdy CaptHowdy 18 minutes ago
RECOMMENDED.... nothing is offical yet, unnecessary twisting of facts to bolster your negative viewpoints. Thats news is two months old
GRLT
axelvento axelvento 18 minutes ago
Cancer vaccines: What’s ahead in 2025

The spotlight is on mRNA-4157 (V940)

https://gulfnews.com/special-reports/cancer-vaccines-whats-ahead-in-2025-1.500010233
MRNA
facts_matter14 facts_matter14 19 minutes ago
Does this sound like a company with 16 products and a 17th on the way?

https://investorshub.advfn.com/uimage/uploads/2024/12/24/mwowsIMG_6034.png








.
SRMX
HomerRomer HomerRomer 19 minutes ago
More testimony videos from trial participants like the Australian news reel of Ern Heaven would be amazing. I would think that most of the people involved 9 years ago in the earlier phase studies have passed on since the average life expectancy is normally between 3-11 years after being diagnosed w
AVXL
CaptHowdy CaptHowdy 20 minutes ago
That's how to make money on the OTC. 🤦🏻‍♂️ Anyone could do it; only if the effort spent discounting the new leadership in place along with the turn around story underway was used to turn a profit vs. using 9yr old DD to bad mouth new CEO.
GRLT
crescentmotor crescentmotor 21 minutes ago
I think that is a bad precedent to start.

100% on parading a handful of Blarcamesine patients at the JPM conference. I highly doubt AVXL would involve itself with anecdotal gimmicks where there is no way possible to extrapolate isolated successes to meaningful conclusions about broad
AVXL JPM
Steady_T Steady_T 23 minutes ago
MABS are the current standard of care, so Blarcamesine has to be better than the MABS, which is not saying much.

I suspect that if Blarcamesine was the equal of the MABS is would still be approved on safety and cost grounds.

As has been pointed out multiple times on the
AVXL
facts_matter14 facts_matter14 25 minutes ago
Looks like Baggy is worried about Maxine not showing up at CES this week…………….









.
SRMX
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 25 minutes ago
Anavex has delayed PD in order to wait out the development of a reliable biomarker, which has happened only during the past few months.

OK so we should see the test start this quarter then?
AVXL
Canna_Business Canna_Business 25 minutes ago
$FKINX $IONQ $FFALX $MRMD $RKLB $XOM $DUK $LNVGY $V $SOFI $BICEY $VOO $TEMWX
BICEY DUK FFALX
mrfence mrfence 25 minutes ago
Actually, these issues traded on the NYSE under conservatorship and the FHFA made a decision to voluntarily delist Fannie and Freddie from the NYSE. There's Companies in bankruptcy like Gamestop, GME, trading on Big Boards. Unfortunately, the ball's in Gooberment's as to when they see fit to up lis
GME
Canna_Business Canna_Business 25 minutes ago
$FKINX $IONQ $FFALX $MRMD $RKLB $XOM $DUK $LNVGY $V $SOFI $BICEY $VOO $TEMWX
BICEY DUK FFALX
eb0783 eb0783 26 minutes ago
Thanks TJG. I never thought the subject needed any discussion......it was so obvious. Yet some feel they should denigrate the company for not saying it over and over.

Our Story
Affluence Corporation (OTC PINK:AFFU) was incorporated in 2008 and initially operated as a social net
AFFU
Canna_Business Canna_Business 26 minutes ago
$MRMD
MRMD

Your Recent History

Delayed Upgrade Clock